PE14896A1 - Aminoalcanimidazoles y triazoles acilados - Google Patents
Aminoalcanimidazoles y triazoles aciladosInfo
- Publication number
- PE14896A1 PE14896A1 PE1995268750A PE26875095A PE14896A1 PE 14896 A1 PE14896 A1 PE 14896A1 PE 1995268750 A PE1995268750 A PE 1995268750A PE 26875095 A PE26875095 A PE 26875095A PE 14896 A1 PE14896 A1 PE 14896A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- preferred
- alkyl
- piridyl
- phenyl
- Prior art date
Links
- 150000003852 triazoles Chemical class 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 AMINO Chemical class 0.000 abstract 1
- ZBJJDYGJCNTNTH-UHFFFAOYSA-N Betahistine mesilate Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CNCCC1=CC=CC=N1 ZBJJDYGJCNTNTH-UHFFFAOYSA-N 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Lubricants (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA I DONDE: R1 ES FENILO, NAFTILO, TIENILO o PIRIDILO, OPCIONALMENTE MONOSUSTITUIDO POR HALOGENO, ALCOXI, ALQUILO, DIALQUILAMINO o CIANO, DE PREFERENCIA FENILO; CUANDO R1 ES DIFERENTE DE FENILO, ES PREFERIBLEMENTE HIDROGENO. R2 ES H; SI R1 ES H, R2 ES PIRIDILO o 2-(5-CLORO)PIRIDILO; R3 ES H, HALOGENO, DE PREFERENCIA CLORO, ALQUILO, CIANO, ALCOXICARBONILO, ALQUILCARBONILO o AMINO OPCIONALMENTE SUSTITUIDO, DE PREFERENCIA ES HALOGENO EN POSICION 4; X ES CH o N, DE PREFERENCIA CH. ESTOS COMPUESTOS SE CARACTERIZAN POR PRESENTARSE EN FORMA LIBRE O EN FORMA DE SAL, TAMBIEN POR SU USO COMO INHIBIDORES SELECTIVOS DE LA 25-HIDROXIVITAMINA D3-HIDROXILASA EN EL TRATAMIENTO DE PADECIMIENTOS DE PROLIFERACION Y DIFERENCIACION EN LOS TEJIDOS EN RESPUESTA A LA VITAMINA D.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9409882A GB9409882D0 (en) | 1994-05-18 | 1994-05-18 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE14896A1 true PE14896A1 (es) | 1996-05-09 |
Family
ID=10755289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1995268750A PE14896A1 (es) | 1994-05-18 | 1995-05-16 | Aminoalcanimidazoles y triazoles acilados |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5622982A (es) |
| EP (1) | EP0683156B1 (es) |
| JP (1) | JP2912566B2 (es) |
| KR (1) | KR100371465B1 (es) |
| CN (1) | CN1060163C (es) |
| AT (1) | ATE164576T1 (es) |
| AU (1) | AU696880B2 (es) |
| BR (1) | BR9502062A (es) |
| CA (1) | CA2149459C (es) |
| CO (1) | CO4290423A1 (es) |
| CZ (1) | CZ285385B6 (es) |
| DE (1) | DE69501915T2 (es) |
| DK (1) | DK0683156T3 (es) |
| ES (1) | ES2114289T3 (es) |
| FI (1) | FI112364B (es) |
| GB (1) | GB9409882D0 (es) |
| GR (1) | GR3026505T3 (es) |
| HK (1) | HK1008743A1 (es) |
| HU (1) | HUT72063A (es) |
| IL (1) | IL113743A (es) |
| MY (1) | MY135559A (es) |
| NO (1) | NO304738B1 (es) |
| NZ (1) | NZ272129A (es) |
| PE (1) | PE14896A1 (es) |
| PH (1) | PH31510A (es) |
| RU (1) | RU2152933C2 (es) |
| SI (1) | SI0683156T1 (es) |
| SK (1) | SK280326B6 (es) |
| TW (1) | TW351718B (es) |
| ZA (1) | ZA954074B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0708771B1 (en) * | 1993-07-15 | 1998-10-07 | Pfizer Inc. | Benzyloxyquinuclidines as substance p antagonists |
| US6162801A (en) * | 1995-11-20 | 2000-12-19 | Kita; Kiyoshi | External ophthalmic preparation containing vitamin D |
| EP0998925A4 (en) * | 1997-05-26 | 2003-02-26 | New Vision Co Ltd | TOPICAL ADMINISTRATION COMPOSITIONS CONTAINING VITAMINS D AND VITAMINS K |
| US6034251A (en) * | 1997-11-07 | 2000-03-07 | Schering Corporation | Phenyl-alkyl-imidazoles |
| TW575562B (en) * | 1998-02-19 | 2004-02-11 | Agrevo Uk Ltd | Fungicides |
| IL129596A (en) * | 1998-05-08 | 2003-10-31 | Dow Agrosciences Llc | Preparation of 2-substituted pyridines |
| GB0029524D0 (en) * | 2000-12-04 | 2001-01-17 | Univ Sheffield | Disease treatment |
| GB0128415D0 (en) * | 2001-11-27 | 2002-01-16 | Univ Sheffield | Medicaments |
| JP2004196795A (ja) * | 2002-12-16 | 2004-07-15 | Wyeth | 外部寄生虫駆除剤としてのｎ−フェニル−３−シクロプロピルピラゾール−４−カルボニトリル |
| US7429604B2 (en) * | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2006032299A1 (en) * | 2004-09-24 | 2006-03-30 | Susanna Miettinen | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| US20060078494A1 (en) * | 2004-09-24 | 2006-04-13 | Sapphire Therapeutics, Inc. | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| CN104530038A (zh) * | 2014-12-10 | 2015-04-22 | 沈阳药科大学 | 酰胺咪唑类衍生物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2041771C3 (de) * | 1970-08-22 | 1979-07-26 | Bayer Ag, 5090 Leverkusen | derivate |
| US4191767A (en) * | 1977-01-07 | 1980-03-04 | Westwood Pharmaceuticals, Inc. | Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines |
| IT1097314B (it) * | 1978-07-26 | 1985-08-31 | Recordati Chem Pharm | Derivati dell'imidazolo ad attivita' anticonvulsivante |
| CH655103A5 (de) * | 1983-03-11 | 1986-03-27 | Sandoz Ag | Azolderivate, verfahren zu ihrer herstellung und ihre verwendung. |
| CH677925A5 (es) * | 1986-12-03 | 1991-07-15 | Sandoz Ag | |
| DE3644616A1 (de) * | 1986-12-29 | 1988-07-07 | Lentia Gmbh | Imidazolderivate, verfahren zur herstellung und deren verwendung |
| IT1237792B (it) * | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
-
1994
- 1994-05-18 GB GB9409882A patent/GB9409882D0/en active Pending
-
1995
- 1995-05-16 DK DK95810325T patent/DK0683156T3/da active
- 1995-05-16 MY MYPI95001281A patent/MY135559A/en unknown
- 1995-05-16 CA CA002149459A patent/CA2149459C/en not_active Expired - Fee Related
- 1995-05-16 CZ CZ951265A patent/CZ285385B6/cs not_active IP Right Cessation
- 1995-05-16 DE DE69501915T patent/DE69501915T2/de not_active Expired - Lifetime
- 1995-05-16 ES ES95810325T patent/ES2114289T3/es not_active Expired - Lifetime
- 1995-05-16 SK SK635-95A patent/SK280326B6/sk not_active IP Right Cessation
- 1995-05-16 RU RU95107652/04A patent/RU2152933C2/ru not_active IP Right Cessation
- 1995-05-16 AT AT95810325T patent/ATE164576T1/de not_active IP Right Cessation
- 1995-05-16 SI SI9530063T patent/SI0683156T1/xx not_active IP Right Cessation
- 1995-05-16 FI FI952383A patent/FI112364B/fi active
- 1995-05-16 IL IL11374395A patent/IL113743A/xx not_active IP Right Cessation
- 1995-05-16 NO NO951944A patent/NO304738B1/no not_active IP Right Cessation
- 1995-05-16 PE PE1995268750A patent/PE14896A1/es not_active Application Discontinuation
- 1995-05-16 US US08/442,053 patent/US5622982A/en not_active Expired - Lifetime
- 1995-05-16 AU AU20089/95A patent/AU696880B2/en not_active Ceased
- 1995-05-16 EP EP95810325A patent/EP0683156B1/en not_active Expired - Lifetime
- 1995-05-16 NZ NZ272129A patent/NZ272129A/en not_active IP Right Cessation
- 1995-05-17 JP JP7118345A patent/JP2912566B2/ja not_active Expired - Fee Related
- 1995-05-17 HU HU9501451A patent/HUT72063A/hu not_active Application Discontinuation
- 1995-05-17 BR BR9502062A patent/BR9502062A/pt not_active IP Right Cessation
- 1995-05-17 CO CO95021039A patent/CO4290423A1/es unknown
- 1995-05-17 KR KR1019950012172A patent/KR100371465B1/ko not_active Expired - Fee Related
- 1995-05-17 CN CN95106034A patent/CN1060163C/zh not_active Expired - Fee Related
- 1995-05-17 PH PH50532A patent/PH31510A/en unknown
- 1995-05-18 ZA ZA954074A patent/ZA954074B/xx unknown
- 1995-05-19 TW TW084105010A patent/TW351718B/zh not_active IP Right Cessation
-
1998
- 1998-04-03 GR GR980400688T patent/GR3026505T3/el unknown
- 1998-07-20 HK HK98109296A patent/HK1008743A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE14896A1 (es) | Aminoalcanimidazoles y triazoles acilados | |
| HUP0300693A2 (hu) | Eljárás epotilon-analógok és -intermedierek előállítására | |
| ES2084347T3 (es) | Derivados de 5-heteroil-indol. | |
| MX9202287A (es) | Nuevos derivados de perhidroisoindol, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
| NO905066D0 (no) | Isoindolonderivater, deres fremstilling og anvendelser. | |
| DE69728544D1 (de) | Totalsynthese von acylfulvenen mit antitumorwirkung | |
| SI0773943T1 (en) | Compounds useful as antiproliferative agents and garft inhibitors | |
| CO4990932A1 (es) | Derivados de 2,1,3-benzotiadiazol y proceso para su preparacion | |
| NZ228065A (en) | 1,2,4-triazinediones and parasiticidal compositions; processes for preparation | |
| DE60038902D1 (de) | Verwendung von prostanoid-ep4-rezeptor-antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten | |
| ATE215555T1 (de) | 17-beta.-allyloxy(thio)alkyl-androstan derivative zur modulation von meiose | |
| ATE119532T1 (de) | 7-oxabicycloheptyl-substituierte, heterocyclische amid-prostaglandin-analoge, verwendbar bei der behandlung von vasospastischen und thrombotischen krankheiten. | |
| DK0684237T3 (da) | Morpholinderivater | |
| DE69821142D1 (de) | Verwendung von prostanoiden-antagonisten zur bhandlung von primären kopfschmerzen | |
| DE69827614D1 (de) | Chinoxalindionen | |
| DE60013515D1 (de) | 4-Arylpiperidinderivate zur Behandlung von Pruritus | |
| CO4410332A1 (es) | Oxazoles y tiazoles sustituidos | |
| ATE93679T1 (de) | Diphenylaether und isothiazolone enthaltende antialgenmittel, methode zur bekaempfung von algen und die antialgenmittel enthaltende ueberzugmaterialien. | |
| EP0192951B1 (en) | 5-sulfonamido-1-aryl pyrazoles | |
| ATE130852T1 (de) | Verfahren zur reinigung von 7-chlor-chinolin-8- carbonsäuren. | |
| AR000385A1 (es) | Proceso para la producción de derivados de 4-alcoxiimino-6-(5-hidroxipi razol-4-il)-tiocromano-1,1-dioxido y compuestos intermediarios de aplicación en dicho proceso y preparación de dichos compuestos intermediarios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |